Last reviewed · How we verify

Hydroxychloroquine Oral Product

Hospital do Coracao · Phase 3 active Small molecule

Hydroxychloroquine Oral Product is a Antimalarial immunomodulator Small molecule drug developed by Hospital do Coracao. It is currently in Phase 3 development for Systemic lupus erythematosus, Rheumatoid arthritis, Malaria prophylaxis and treatment.

Hydroxychloroquine is an antimalarial and immunomodulatory agent that inhibits toll-like receptor signaling and reduces inflammatory cytokine production.

Hydroxychloroquine is an antimalarial and immunomodulatory agent that inhibits toll-like receptor signaling and reduces inflammatory cytokine production. Used for Systemic lupus erythematosus, Rheumatoid arthritis, Malaria prophylaxis and treatment.

At a glance

Generic nameHydroxychloroquine Oral Product
SponsorHospital do Coracao
Drug classAntimalarial immunomodulator
TargetToll-like receptors (TLR), lysosomal pH modulation
ModalitySmall molecule
Therapeutic areaImmunology, Rheumatology
PhasePhase 3

Mechanism of action

Hydroxychloroquine accumulates in lysosomes and endosomes, where it raises pH and interferes with antigen presentation and toll-like receptor activation. This reduces the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-17, making it useful in autoimmune and inflammatory conditions. It also has weak anticoagulant properties and may reduce thrombotic risk in certain conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hydroxychloroquine Oral Product

What is Hydroxychloroquine Oral Product?

Hydroxychloroquine Oral Product is a Antimalarial immunomodulator drug developed by Hospital do Coracao, indicated for Systemic lupus erythematosus, Rheumatoid arthritis, Malaria prophylaxis and treatment.

How does Hydroxychloroquine Oral Product work?

Hydroxychloroquine is an antimalarial and immunomodulatory agent that inhibits toll-like receptor signaling and reduces inflammatory cytokine production.

What is Hydroxychloroquine Oral Product used for?

Hydroxychloroquine Oral Product is indicated for Systemic lupus erythematosus, Rheumatoid arthritis, Malaria prophylaxis and treatment, Porphyria cutanea tarda.

Who makes Hydroxychloroquine Oral Product?

Hydroxychloroquine Oral Product is developed by Hospital do Coracao (see full Hospital do Coracao pipeline at /company/hospital-do-coracao).

What drug class is Hydroxychloroquine Oral Product in?

Hydroxychloroquine Oral Product belongs to the Antimalarial immunomodulator class. See all Antimalarial immunomodulator drugs at /class/antimalarial-immunomodulator.

What development phase is Hydroxychloroquine Oral Product in?

Hydroxychloroquine Oral Product is in Phase 3.

What are the side effects of Hydroxychloroquine Oral Product?

Common side effects of Hydroxychloroquine Oral Product include Retinopathy, Gastrointestinal disturbance (nausea, diarrhea), Headache, Pruritus, Cardiomyopathy (rare, with long-term use).

What does Hydroxychloroquine Oral Product target?

Hydroxychloroquine Oral Product targets Toll-like receptors (TLR), lysosomal pH modulation and is a Antimalarial immunomodulator.

Related